Early Detection of Sporadic Pancreatic Cancer: Strategic Map for Innovation—A White Paper
Open accessAbstract
Innovation leading to significant advances in research and subsequent translation to clinical practice is urgently necessary in early detection of sporadic pancreatic cancer. Addressing this need, the Early Detection of Sporadic Pancreatic Cancer Summit Conference was conducted by Kenner Family Research Fund in conjunction with the 2014 American Pancreatic Association and Japan Pancreas Society Meeting. International interdisciplinary scientific representatives engaged in strategic facilitated conversations based on distinct areas of inquiry: Case for Early Detection: Definitions, Detection, Survival, and Challenges; Biomarkers for Early Detection; Imaging; and Collaborative Studies. Ideas generated from the summit have led to the development of a Strategic Map for Innovation built upon 3 components: formation of an international collaborative effort, design of an actionable strategic plan, and implementation of operational standards, research priorities, and first-phase initiatives. Through invested and committed efforts of leading researchers and institutions, philanthropic partners, government agencies, and supportive business entities, this endeavor will change the future of the field and consequently the survival rate of those diagnosed with pancreatic cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Screening the general population for pancreatic ductal adenocarcinoma carries risk, and there is currently no evidence that it reduces mortality or is cost-effective.
“Screening of the general population carries risk, and there is currently no evidence that it reduces mortality or is cost-effective.54,55”
From Early detection of pancreatic cancer (2020) · cites this paper as [54]
International guidelines and a white paper on early detection recommend targeted screening of individuals whose lifetime risk of pancreatic ductal adenocarcinoma is higher than 5%.
“However, international guidelines and a white paper on the early detection of pancreatic ductal adenocarcinoma recommend targeted screening of individuals whose lifetime risk of developing pancreatic ductal adenocarcinoma is higher than 5% (figure 1).6,54”
From Early detection of pancreatic cancer (2020) · cites this paper as [54]
Except for jaundice, weight loss, and new-onset diabetes, most individual risk factors or symptoms provide only a modest 1.5-fold to 3-fold increased risk of developing pancreatic ductal adenocarcinoma.
“With the exception of jaundice, weight loss, and new-onset diabetes, which indicate a considerably increased risk, most individual risk factors or symptoms (eg, dyspepsia, bloating, change in bowel habit) only provide a modest (1·5-fold to 3-fold) increased risk of developing pancreatic ductal adenocarcinoma.10,54”
From Early detection of pancreatic cancer (2020) · cites this paper as [54]
The 5% lifetime-risk target group includes individuals with at least two first-degree relatives with pancreatic ductal adenocarcinoma, patients with hereditary pancreatitis or particular genetic syndromes, and individuals with mucinous cystic lesions of the pancreas.
“This target includes individuals with at least two first-degree relatives with pancreatic ductal adenocarcinoma, patients with hereditary pancreatitis or particular genetic syndromes (eg, Peutz-Jeghers syndrome, or germline mutations in the CDKN2A, BRCA2, or PALB2),6,54 and individuals with mucinous cystic lesions of the pancreas.19–21”
From Early detection of pancreatic cancer (2020) · cites this paper as [54]
The US Preventive Services Task Force and other guidelines recommend against screening for pancreatic ductal adenocarcinoma in asymptomatic adults at average risk.
“The US Preventive Services Task Force and other guidelines recommend against screening for pancreatic ductal adenocarcinoma in asymptomatic adults at average risk.6,53,54”
From Early detection of pancreatic cancer (2020) · cites this paper as [54]
All screening programmes for pancreatic ductal adenocarcinoma aim to detect and treat T1N0M0 cancers or high-grade dysplastic premalignant lesions.
“All screening programmes for pancreatic ductal adenocarcinoma aim to detect and treat T1N0M0 cancers or high-grade dysplastic premalignant lesions (ie, pancreatic intraepithelial neoplasia 3 or mucinous cystic tumours with high-grade dysplasia).6,54”
From Early detection of pancreatic cancer (2020) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · see citing works
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals
Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.005 · Cited by 648 · see citing works
Early Detection of Sporadic Pancreatic Cancer: Summative Review
Chari, S. T., Kelly, K., Hollingsworth, M. A., Thayer, S. P., Ahlquist, D. A., Andersen, D. K., Batra, S. K., Brentnall, T. A., Canto, M., Cleeter, D. F., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000368 · Cited by 295 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482 · see citing works
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158 · see citing works
Self-citationChari, S. T., Maitra, A., Matrisian, L. M., Shrader, E. E., Wu, B. U., Kambadakone, A., Zhao, Y.-Q., Kenner, B., Rinaudo, J. A. S., Srivastava, S., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106659 · Cited by 62 · see citing works
Self-citationEarly Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers
Kenner, B. J., Go, V. L. W., Chari, S. T., Goldberg, A. E., & Rothschild, L. J. (2017) · Pancreas · doi:10.1097/mpa.0000000000000939 · Cited by 24 · see citing works
Self-citation
- Authors
- Kenner, B. J., Chari, S. T., Cleeter, D. F., & Go, V. L. W.
- Affiliations
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- Corresponding author
- Kenner, Barbara J.
- Venue
- Pancreas
- Published
- 2015-07
- Volume
- 44
- Issue
- 5
- Pages
- 686-692
- ISSN
- 0885-3177 (ISSN-L)
- PMC
- PMC4467583
- OpenAlex
- W1993470817
- Cited by
- 56
- References
- 3
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 5 · 2019: 2 · 2018: 8 · 2017: 5 · 2016: 4 · 2015: 1 · 2014: 2
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Pancreas (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (P01CA163200)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- sporadic pancreatic cancer, early detection, biomarkers, pancreatic cancer imaging, international research collaboration, strategic planning, cancer survival, translational research
- MeSH terms
- Biopsy, Cooperative Behavior, Diagnostic Imaging, Diffusion of Innovation, Humans, International Cooperation, Pancreatic Neoplasms, Predictive Value of Tests, Prognosis, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal, Molecular Diagnostic Techniques, Interdisciplinary Communication, Biomedical Research, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
